Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care products gorilla Johnson & Johnson (NYSE:JNJ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.

J&J facts

Headquarters (founded)

New Brunswick, N.J. (1886)

Market Cap

$205.6 billion



Trailing-12-Month Revenue

$67.2 billion


Chairman/CEO Alex Gorsky
CFO Dominic Caruso

Return on Equity (average, past 3 years)



$19.8 billion / $16.9 billion

Dividend Yield




Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 14,045 members who have rated J&J believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, brenoboyle, succinctly summed up J&J bull case for our community:

[J&J] has had some nice quarterly reports recently, looks undervalued by cash flow and seems to be in the midst of a successful turnaround. They are controlling costs and leveraging the firm's comparative advantage.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.